Tremelimumab Plus Durvalumab in Advanced Hepatocellular Carcinoma Treatment: A Pharmacovigilance Comparative Analysis Between Eudravigilance and HIMALAYA Study
{{output}}
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally. Recent advancements in systemic therapy, particularly the combination of durvalumab and tremelimumab - dual immune checkpoin... ...
